FineMark National Bank & Trust decreased its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 2.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 122,423 shares of the biopharmaceutical company’s stock after selling 3,106 shares during the period. FineMark National Bank & Trust’s holdings in Bristol-Myers Squibb were worth $6,821,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Welch Investments LLC grew its holdings in shares of Bristol-Myers Squibb by 3.9% during the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 79 shares during the period. Crestwood Advisors Group LLC purchased a new position in shares of Bristol-Myers Squibb during the 1st quarter worth approximately $116,000. Blue Chip Partners Inc. grew its holdings in shares of Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 17 shares during the period. Proficio Capital Partners LLC grew its holdings in shares of Bristol-Myers Squibb by 29.6% during the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 504 shares during the period. Finally, American National Bank grew its holdings in shares of Bristol-Myers Squibb by 11.7% during the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 225 shares during the period. Hedge funds and other institutional investors own 68.88% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb Company (BMY) Shares Sold by FineMark National Bank & Trust” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/bristol-myers-squibb-company-bmy-shares-sold-by-finemark-national-bank-trust/1579227.html.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Theodore R. Samuels II acquired 6,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by insiders.

A number of research analysts have weighed in on the company. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Wednesday, August 16th. BMO Capital Markets reiterated an “underperform” rating and set a $47.00 target price (down previously from $51.00) on shares of Bristol-Myers Squibb in a report on Wednesday, July 26th. Leerink Swann reduced their target price on Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a report on Friday, July 28th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Finally, Cowen and Company reiterated a “hold” rating and set a $65.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $62.20.

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at 63.33 on Friday. The stock has a market capitalization of $103.86 billion, a P/E ratio of 23.13 and a beta of 1.18. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $63.74. The firm’s 50-day moving average price is $58.94 and its 200 day moving average price is $56.02.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same period in the previous year, the company earned $0.69 earnings per share. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 2.46%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.